Monograph Details
|
|
Neoplasms
> Miscellaneous oncology agents
|
|
AREDIA |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Bisphosphonate. |
| Generic Name |
|
Pamidronate disodium 30mg, 90mg; per vial; pwd for IV infusion after reconstitution; contains mannitol. |
| Indications |
|
Hypercalcemia of malignancy. Paget's disease. Osteolytic bone metastases of breast cancer. Osteolytic lesions of multiple myeloma. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion. Hypercalcemia of malignancy: Assure adequate hydration; give as a single dose infused over 2–24hrs; moderate disease (albumin-corrected serum calcium 12–13.5mg/dL): 60–90mg; severe disease (albumin-corrected serum calcium >13.5mg/dL): 90mg; allow at least 7 days before retreating. Paget's disease: 30mg daily infused over 4hrs on 3 consecutive days for a total of 90mg. Osteolytic bone lesions of multiple myeloma: 90mg infused over 4hrs once monthly. Osteolytic bone metastases: 90mg infused over 2hrs every 3-4 weeks. Max single dose: 90mg. |
| Precautions |
|
Severe renal impairment in patients with bone metastases: not recommended. Renal or hepatic insufficiency. Check serum creatinine before each dose: withhold until serum creatinine is within 10% of baseline if serum creatinine increases 0.5mg/dL from normal pre-treatment levels, or by 1mg/dL from an abnormal pre-treatment level. Monitor electrolytes (esp. calcium, magnesium, phosphate, potassium), CBC/differential, hematocrit/hemoglobin. Pre-existing blood disorders (eg, anemia, leukopenia, thrombocytopenia); monitor closely for first 2 weeks after treatment. Avoid dental surgery (do preventative dental work before therapy). Pregnancy (Cat.D): not recommended. Nursing mothers. |
| Interactions |
|
Caution with other nephrotoxic drugs. |
| Adverse Reactions |
|
Infusion-site reactions, fever, headache, dizziness, paresthesia, increased sweating, GI upset, anemia, fatigue, musculoskeletal pain (may be severe), electrolyte disturbances, hypertension, dyspnea, renal toxicity; rare: jaw osteonecrosis. |
| How Supplied |
Vials 30mg—4
90mg—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
